Trial Profile

Window-of-opportunity Umbrella Platform Trial of Short-course Pre-operative Targeted Treatments in Patients With Molecularly Selected and Resectable Primary Colorectal Cancer: the UNICORN Study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Balstilimab (Primary) ; Botensilimab (Primary) ; CR 6086 (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Panitumumab (Primary) ; Sotorasib (Primary) ; Trastuzumab-deruxtecan (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use
Acronyms UNICORN

Most Recent Events

17 Jun 2025 Trial protocol amended with addition of CR-6086, Nivolumab, and Sotorasib drug.
11 Jun 2025 Planned number of patients changed from 112 to 140.
26 Feb 2025 According to an Agenus media release, data from the study is presented at ASCO GI 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com